Many different types of cancer, including renal cell carcinoma, glioblastoma, thymic carcinoma, nasopharyngeal carcinoma, T-anaplastic large-cell lymphoma, Waldenström’s macroglobulinemia, and Hodgkin and non-Hodgkin lymphomas, may respond well to therapies that target CD70 (13, 15, 23–28). Here, CD70 is linked to glioblastoma.